China Oncology ›› 2022, Vol. 32 ›› Issue (1): 13-23.doi: 10.19401/j.cnki.1007-3639.2022.01.002
• Article • Previous Articles Next Articles
LIN Yi, WANG Ce, KANG Xun, KANG Zhuang, CHEN Feng, JIANG Bo, LI Wenbin()
Received:
2021-07-05
Revised:
2021-12-09
Online:
2022-01-30
Published:
2022-01-25
Contact:
LI Wenbin
E-mail:liwenbin@ccmu.edu.cn
CLC Number:
LIN Yi, WANG Ce, KANG Xun, KANG Zhuang, CHEN Feng, JIANG Bo, LI Wenbin. Screening recurrent glioblastoma-related genes and analyzing their gene expressions in association with clinicopathological parameters and prognosis[J]. China Oncology, 2022, 32(1): 13-23.
Tab. 3
GSE62153 GO function analysis"
Category | Term | Description | Count n (%) | P value | Gene |
---|---|---|---|---|---|
BP | GO: 0007417 | Central nervous system development | 4 (12.01) | 0.001 | SH3GL3, MOG, SH3GL2, KLK6 |
CC | GO: 0043209 | Myelin sheath | 4 (12.10) | 0.002 | CLDN11, MOBP, PLP1, ERMN |
MF | GO: 0003779 | Actin binding | 4 (12.10) | 0.011 | MYBPC1, MOBP, DAAM2, PHACTR3 |
BP | GO: 0022010 | Central nervous system myelination | 2 (6.06) | 0.012 | NKX6-2, PLP1 |
BP | GO: 0008366 | Axon ensheathment | 2 (6.06) | 0.012 | CLDN11, PLP1 |
MF | GO: 0008599 | Protein phosphatase type 1 regulator activity | 2 (6.06) | 0.016 | PPP1R1B, PHACTR3 |
MF | GO: 0019911 | Structural constituent of myelin sheath | 2 (6.06) | 0.016 | MOBP, PLP1 |
BP | GO: 0019371 | Cyclooxygenase pathway | 2 (6.06) | 0.018 | AKR1C3, PTGDS |
MF | GO: 0031432 | Titin binding | 2 (6.06) | 0.023 | MYBPC1, CAPN3 |
BP | GO: 0006796 | Phosphate-containing compound metabolic process | 2 (6.06) | 0.032 | ENPP2, LHPP |
MF | GO: 0042802 | Identical protein binding | 5 (15.15) | 0.034 | CLDN11, SH3GL3, HSPB8, SH3GL2, ETNPPL |
Fig. 5
Survival analysis of TCGA and CGGA database The higher expression groups were favorable than those of patients with lower expression. A: Analysis of ERMN expression in TCGA database; B: Analysis of MOG expression in TCGA database; C: Analysis of MOBP expression in TCGA database; D: Analysis of ERMN expression in CGGA database; E: Analysis of MOG Expression in CGGA database; F: Analysis of MOBP expression in CGGA database."
Fig. 6
mRNA expression of ERMN, MOG and MOBP genes in control tissues and glioma tissues N: Control tissues; T: Glioma tissues. A: mRNA expression of ERMN gene in control tissues and glioma tissues; B: mRNA expression of MOG gene in control tissues and glioma tissues; C: mRNA expression of MOBP gene in control tissues and glioma tissues; D: mRNA expression of ERMN gene in different WHO grades of glioma; E: mRNA expression of MOG gene in different WHO grades of glioma; F: mRNA expression of MOBP gene in different WHO grades of glioma. *: P<0.05, compared with control tissues."
Tab. 5
Association between ERMN, MOG and MOBP genes expressions and the patient's clinicopathological characteristics in patients with glioma (n)"
Clinicopathological Features | Case | ERMN Expression | MOG Expression | MOBP Expression | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Low | High | P value | Low | High | P value | Low | High | P value | ||
Gender | ||||||||||
Male | 203 | 109 | 94 | 0.170 | 104 | 99 | 0.620 | 106 | 97 | 0.270 |
Female | 122 | 56 | 66 | 59 | 63 | 56 | 66 | |||
Age/year | ||||||||||
≤40 | 143 | 65 | 78 | 0.090 | 64 | 79 | 0.084 | 61 | 82 | 0.022 |
>40 | 182 | 100 | 82 | 99 | 83 | 101 | 81 | |||
WHO Grade | ||||||||||
Ⅱ | 103 | 29 | 74 | <0.001 | 28 | 75 | <0.001 | 24 | 79 | <0.001 |
Ⅲ | 79 | 37 | 42 | 37 | 42 | 39 | 40 | |||
Ⅳ | 139 | 96 | 43 | 95 | 44 | 96 | 43 | |||
MGMT methylation status | ||||||||||
Un-methylated | 149 | 82 | 67 | 0.250 | 78 | 71 | 0.640 | 85 | 64 | 0.029 |
Methylated | 157 | 76 | 81 | 78 | 79 | 70 | 87 | |||
IDH mutation status | ||||||||||
Wild type | 149 | 97 | 52 | <0.001 | 96 | 53 | <0.001 | 99 | 50 | <0.001 |
Mutant | 175 | 67 | 108 | 66 | 109 | 62 | 113 | |||
Type of tumorigenesis | ||||||||||
Primary | 229 | 116 | 113 | 0.900 | 117 | 112 | 0.780 | 113 | 116 | 0.910 |
Recurrent | 62 | 30 | 32 | 29 | 33 | 30 | 32 | |||
Secondary | 30 | 16 | 14 | 14 | 16 | 16 | 14 | |||
Histology | ||||||||||
Strocytoma | 56 | 17 | 39 | <0.001 | 16 | 40 | <0.001 | 13 | 43 | <0.001 |
Oligodendroglioma | 52 | 14 | 38 | 14 | 38 | 14 | 38 | |||
Anaplastic oligodendro | 12 | 5 | 7 | 4 | 8 | 5 | 7 | |||
Anaplastic astrocytoma | 62 | 30 | 32 | 31 | 31 | 31 | 31 | |||
Glioblastoma | 139 | 96 | 43 | 95 | 44 | 96 | 43 |
[1] |
OSTROM Q T, PATIL N, CIOFFI G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017[J]. Neuro Oncol, 2020, 22(12 suppl 2): iv1-iv96.
doi: 10.1093/neuonc/noaa200 |
[2] | MEYER M A. Malignant gliomas in adults[J]. N Engl J Med, 2008, 359(17): 1850. |
[3] |
GRUBER M L, BUSTER W P. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma[J]. Am J Clin Oncol, 2004, 27(1): 33-38.
doi: 10.1097/01.coc.0000045852.88461.80 |
[4] |
BAO Z S, CHEN H M, YANG M Y, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas[J]. Genome Res, 2014, 24(11): 1765-1773.
doi: 10.1101/gr.165126.113 |
[5] |
ZHAO Z, MENG F, WANG W, et al. Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas[J]. Sci Data, 2017, 4: 170024.
doi: 10.1038/sdata.2017.24 |
[6] |
NIEDER C, GROSU A L, MOLLS M. A comparison of treatment results for recurrent malignant gliomas[J]. Cancer Treat Rev, 2000, 26(6): 397-409.
doi: 10.1053/ctrv.2000.0191 |
[7] |
STUPP R, HEGI M E, MASON W P, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10(5): 459-466.
doi: 10.1016/S1470-2045(09)70025-7 |
[8] |
AZOULAY M, SANTOS F, SHENOUDA G, et al. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution[J]. J Neurooncol, 2017, 132(3): 419-426.
doi: 10.1007/s11060-017-2383-2 |
[9] |
FRIEDMAN H S, PRADOS M D, WEN P Y, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma[J]. J Clin Oncol, 2009, 27(28): 4733-4740.
doi: 10.1200/JCO.2008.19.8721 |
[10] |
KONG D S, LEE J I, PARK K, et al. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas[J]. Cancer, 2008, 112(9): 2046-2051.
doi: 10.1002/(ISSN)1097-0142 |
[11] |
SCHNELL O, THORSTEINSDOTTIR J, FLEISCHMANN D F, et al. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma[J]. J Neurooncol, 2016, 130(3): 591-599.
doi: 10.1007/s11060-016-2267-x |
[12] |
STUPP R, WONG E T, KANNER A A, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase Ⅲ trial of a novel treatment modality[J]. Eur J Cancer, 2012, 48(14): 2192-2202.
doi: 10.1016/j.ejca.2012.04.011 |
[13] |
WANG J G, CAZZATO E, LADEWIG E, et al. Clonal evolution of glioblastoma under therapy[J]. Nat Genet, 2016, 48(7): 768-776.
doi: 10.1038/ng.3590 |
[14] |
NANDEESH B N, NASKAR S, SHASHTRI A H, et al. Recurrent glioblastomas exhibit higher expression of biomarkers with stem-like properties[J]. J Neurosci Rural Pract, 2018, 9(1): 86-91.
doi: 10.4103/jnrp.jnrp_417_17 |
[15] | ZHANG R R, POINTER K B, KUO J S, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma[J]. Neurosurgery, 2014, 75(6): N9-10. |
[16] |
KIM J, LEE I H, CHO H J, et al. Spatiotemporal evolution of the primary glioblastoma genome[J]. Cancer Cell, 2015, 28(3): 318-328.
doi: 10.1016/j.ccell.2015.07.013 |
[17] |
SALEK ESFAHANI B, GHARESOURAN J, GHAFOURI-FARD S, et al. Down-regulation of ERMN expression in relapsing remitting multiple sclerosis[J]. Metab Brain Dis, 2019, 34(5): 1261-1266.
doi: 10.1007/s11011-019-00429-w |
[18] |
ZHANG L, XUE Z Y, LIU Q D, et al. Disrupted folate metabolism with anesthesia leads to myelination deficits mediated by epigenetic regulation of ERMN[J]. EBioMedicine, 2019, 43: 473-486.
doi: 10.1016/j.ebiom.2019.04.048 |
[19] |
HOMS A, CODINA-SOLÀ M, RODRÍGUEZ-SANTIAGO B, et al. Genetic and epigenetic methylation defects and implication of the ERMN gene in autism spectrum disorders[J]. Transl Psychiatry, 2016, 6(7): e855.
doi: 10.1038/tp.2016.120 |
[20] |
LINNINGTON C, WEBB M, WOODHAMS P L. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody[J]. J Neuroimmunol, 1984, 6(6): 387-396.
doi: 10.1016/0165-5728(84)90064-X |
[21] |
VOURC'H P, ANDRES C. Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function[J]. Brain Res Brain Res Rev, 2004, 45(2): 115-124.
doi: 10.1016/j.brainresrev.2004.01.003 |
[22] |
KIM S M, WOODHALL M R, KIM J S, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2(6): e163.
doi: 10.1212/NXI.0000000000000163 |
[23] |
KANAREK N, KEYS H R, CANTOR J R, et al. Histidine catabolism is a major determinant of methotrexate sensitivity[J]. Nature, 2018, 559(7715): 632-636.
doi: 10.1038/s41586-018-0316-7 |
[24] | ROMODANOV A P, ZOZULJA J A, SOSNOV J D, et al. Regional chemotherapy of malignant brain tumors with endolumbar methotrexate injection[J]. Zentralbl Neurochir, 1976, 37(3): 161-167. |
[25] |
NIERENBERG D, HARBAUGH R, MAURER L H, et al. Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study[J]. Neurosurgery, 1991, 28(5): 752-761.
doi: 10.1227/00006123-199105000-00023 |
[26] | 李丰展, 盖立平, 杨艳敏, 等. 胶质母细胞瘤术后甲氨蝶呤间质化疗同步放化疗临床观察[J]. 中国实用神经疾病杂志, 2020, 23(17): 1544-1548. |
LI F Z, GAI L P, YANG Y M, et al. Clinical observation on simultaneous sadiotherapy and chemotherapy of methotrexate interstitial chemotherapy after glioblastoma[J]. Chin J Pract Nerv Dis, 2020, 23(17): 1544-1548. | |
[27] | 白玥, 钟晓松, 李文斌. 甲氨蝶呤通过RAS/MAPK/ERK/MYC/CD47信号通路抑制胶质母细胞瘤的生长[J]. 肿瘤代谢与营养电子杂志, 2018, 5(2): 144-150. |
BAI Y, ZHONG X S, LI W B. Glioblastoma progression is inhibited by methotrexate via RAS/MEK/ERK/MYC/CD47 signaling pathways[J]. Electron J Metab Nutr Cancer, 2018, 5(2): 144-150. |
[1] | WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying . Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration [J]. China Oncology, 2021, 31(9): 775-782. |
[2] | XU Ran , WANG Xinyue , FENG Linyuan , HAN Anna , WANG Yixuan , YANG Wanshan , LIU Chao . Expression and biological significance of NCAPD2 in glioma [J]. China Oncology, 2021, 31(9): 789-798. |
[3] | CAI Shumo, TANG Jie, HUANG Xiao, HUANG Xiaowei, LIU Suping, KE Guihao, ZHENG Zhong, CHENG Xi, TANG Meiqin. Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases [J]. China Oncology, 2021, 31(4): 330-334. |
[4] | WU Yuanyuan , WANG Jun , LIU Qinjiang , ZHANG Ming . Analysis of prognostic factors and treatment strategies of anaplastic thyroid carcinoma [J]. China Oncology, 2021, 31(3): 212-220. |
[5] | LU Dasong, FENG Yongjun, WANG Wufeng, MOU Zhonglin, ZHAO Na . Influence of individualized nutrition intervention on quality of life and survival prognosis of patients with locally advanced nasopharyngeal carcinoma [J]. China Oncology, 2021, 31(12): 1202-1208. |
[6] | HUANG Ling , ZOU Yourui , LI Zuoqi , MA Yue , GAO Xinyi , MA Hui . Effect of CHKA gene silencing on biological behavior of glioma cell and its mechanism [J]. China Oncology, 2021, 31(11): 1041-1049. |
[7] | LI Zeng , WU Yi , CHEN Zhuzhong , CHEN Li , LIAO Hong , MAO Dun , XIAO Yingming , XIE Hongping , LI Xiuli , YANG Shengke , ZHOU Shukui , ZHONG Lei , LU Hao , CHEN Yongji . The value of 18 F-PSMA-1007 PET/CT in the early diagnosis and clinical treatment of patients with biochemical recurrence after radical prostatectomy [J]. China Oncology, 2021, 31(11): 1081-1087. |
[8] | HUANG Ling , ZOU Yourui , MA Yue , LI Zhuoqi , GAO Xinyi , ABU Lagu , MA Hui . Expression difference and clinical significance of CHKα in different grades of gliomas [J]. China Oncology, 2021, 31(10): 892-898. |
[9] | YANG Tongqu , HAN Zhitong , ZHAO Weiping , CHEN Yunzhao , ZHANG Dapeng , ZHANG Ruijian . The prognostic value of microfluidic core technology in detecting circulating tumor cells in brain glioma [J]. China Oncology, 2021, 31(10): 905-911. |
[10] | FENG Xiaoshuang , ZHOU Changming , MO Miao , YUAN Jing , SHEN Jie , WANG Zezhou , ZHANG Zhihong , QIN Yiyu , WU Jiong , ZHENG Ying , GUO Xiaomao . Metastasis patterns and survival analysis of 20 000 patients with metastasis from a hospital-based cancer registry database [J]. China Oncology, 2021, 31(1): 11-19. |
[11] | LIU Qian , QIAO Meng , MAO Shiqi , YANG Shuo , LIU Yiwei , ZHAO Chao , LI Xuefei , REN Shengxiang , ZHOU Caicun . Impact of metastatic organ on prognosis in extensive-stage small cell lung cancer [J]. China Oncology, 2021, 31(1): 45-51. |
[12] | FAN Bo , QI Pan , SU Jianzhi , WEI Shufei , ZHANG Xuan , ZHANG Aili . Baseline characteristics and survival analysis of patients with prostate cancer in the Fourth Hospital of Hebei Medical University [J]. China Oncology, 2020, 30(8): 620-625. |
[13] | LU Xiaoteng, XU Qing. A study on factors associated with recurrence of non-small cell lung cancer based on CT image features [J]. China Oncology, 2020, 30(8): 636-640. |
[14] | CHEN Yang , LIU Wei , LI Ruimin , WANG Qifeng , SHEN Xigang , TANG Wei . Radiogenomics: association between BI-RADS mammographic imaging features and the 21-gene recurrence score [J]. China Oncology, 2020, 30(7): 505-511. |
[15] | ZHANG Xiaomeng , MA Ningyi , ZHU Hongcheng , AI Dashan , REN Zhigang . Efficacy and prognostic factors of adjuvant radiotherapy combined with chemotherapy in patients with pancreatic cancer [J]. China Oncology, 2020, 30(7): 519-524. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd